EZH2 - Wikipedia
Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase enzyme (EC 2.1.1.43) encoded by EZH2 gene, that participates in histone methylation and, ultimately, …
EZH2: a novel target for cancer treatment - PubMed
2020年7月28日 · In this review, we summarize the structure and action modes of EZH2, focusing on up-to-date findings regarding the role of EZH2 in cancer initiation, progression, metastasis, …
The roles of EZH2 in cancer and its inhibitors - PMC
EZH2 is involved in the cell cycle, DNA damage repair, cell differentiation, autophagy, apoptosis, and immunological modulation. The main function of EZH2 is to catalyze the methylation of H3 …
小药谈肿瘤免疫：EZH2 - 知乎 - 知乎专栏
最新研究发现zeste同源物2（ EZH2 ）增强子在肿瘤和免疫细胞中的多效性功能， EZH2抑制作为一种极具潜力的方法可以加强现有的免疫治疗，以改善某些癌症患者的预后。
EZH2 Gene - GeneCards | EZH2 Protein | EZH2 Antibody
2024年12月25日 · EZH2 (Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit) is a Protein Coding gene. Diseases associated with EZH2 include Weaver Syndrome and Prc-2 …
基于表观遗传的肿瘤免疫药物：EZH2抑制剂的研究进展
2023年1月15日 · Valemetostat （Ezharmia）是一种强效、选择性、小分子抑制剂，旨在通过靶向EZH1和EZH2对抗表观遗传失调。它是全球第一个获得监管批准的EZH1/EZH2双重抑制剂， …
肿瘤新型治疗靶点：EZH1/2 - 知乎 - 知乎专栏
PRC2是一种多蛋白转录抑制复合物，包含四个核心成分: EZH2及其高度相关的同源物EZH1、胚胎外胚层发育的抑制子 (EED)、zeste 12的抑制子 (SUZ12)和视网膜母细胞肿瘤相关蛋白46和48 …
- [PDF]
EZH2:调节癌症发展的多重表观遗传因子
EZH2 have been detected in diverse cancers, and been associated with tumor malignancy. Therefore, targeting EZH2 and EZH2-mediated signaling pathway will provide us a novel …
EZH2: a novel target for cancer treatment - PMC - PubMed …
In this review, we summarize the structure and action modes of EZH2, focusing on up-to-date findings regarding the role of EZH2 in cancer initiation, progression, metastasis, metabolism, …
全球首创EZH2抑制剂他泽司他（Tazemetostat，达唯珂）适应症、 …
5 天之前 · 他泽司他作用机制. 他泽司他（Tazemetostat，商品名：Tazverik、达唯珂）是由益普生（Ipsen）旗下公司Epizyme开发的全球首创 EZH2甲基转移酶抑制剂 。 它通过抑制EZH2酶 …